Clinical Trial Update: Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 trial compared weekly exenatide against sitagliptin and placebo to assess glycemic effects, safety, and tolerability in type 2 diabetes, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)
• Sitagliptin (sitagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2015-04-23